Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.
about
Subcellular localization of dihydropyrimidine dehydrogenase5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancerProlonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiencyHigh-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathyPharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Fluorouracil and the new oral fluorinated pyrimidines.5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Predicting disease using genomics.Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.Continuous 5-fluorouracil in the treatment of breast cancerMutations at codon 974 of the DPYD gene are a rare event.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumoursEffects of 5-fluorouracil adjuvant treatment of colon cancer.A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityMolecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.Advances in the Pharmacogenomics of Adverse Drug Reactions.Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.Chronobiology. Implications for cancer chemotherapy.A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity.Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients.Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.Genetic variation in dihydropyrimidine dehydrogenase (DPYD) gene in a healthy adult Indian population.Sex Differences in Cancer: Epidemiology, Genetics and Therapy.'Toxgnostics': an unmet need in cancer medicine
P2860
Q24322064-AE4E2BE6-7153-4E8A-972B-C598E5286BD1Q28359288-BF6041C2-9BCF-4172-A981-C8E87B1AF757Q28372607-EFA23BA7-9289-4684-8D90-4AFC89324B79Q28379450-75FD6992-4119-42CA-A5A0-9C53644C25A9Q31144283-E3733629-2629-43D4-9BB1-1F80C86E1265Q32052960-4DB46904-6DBC-45F1-9156-DCF7405F72F2Q33750445-47FAC3DA-3269-414E-B137-338AEF63B0AEQ33810014-AF1D03B0-AD38-4079-97DC-0066B0873BCBQ34761260-A17F24B8-E8A9-4729-B43A-3D88CEF67ABEQ35784521-F667077A-B647-4D87-8C1E-B98CE952D9E7Q35802542-BA8DD595-6CC7-418B-8774-535442B7465DQ36055251-9D10FF15-A615-4378-8804-62E476179AAEQ36079497-CAC8A502-2716-464E-AE76-738D43DD73DFQ36116010-15A43A8D-38D2-4BD2-A605-500FE999AE61Q36117701-886463A8-0906-40FA-B3FD-C17C990EBB86Q36295110-5EE1FCFF-1BD4-437E-9F01-832F81B455B8Q36295138-92AA21FC-9093-43EA-B27B-4BE1F79B9CC4Q36499247-07357A32-CFB7-4D07-AC30-8E869A34BFBBQ36547234-586BA84D-EA73-426B-B452-EC3CCD3E0B4BQ36618173-8E0A4A4F-7EF0-4D13-A03C-38AFB09BD301Q36927562-EDA23475-36E6-4173-B23A-33CD2CC17229Q37290672-5E3D073F-5D73-45FF-B65F-5987A18E3DF6Q37358027-91D1459C-B18E-4FE9-88FB-82A99964994CQ37475866-58A41C12-1E6E-44BD-98D8-7421C430B1A9Q37706746-1B61924D-2EF3-4DD1-AEC6-6EE68470E721Q38663764-75FFE7F7-0C8E-4FF4-B523-F3E684E20614Q39208906-F2EA97AD-2E55-4F62-ABCF-5F05392B5C5CQ40405359-A3C3BE86-7053-44DE-8F40-D3FDE65C3841Q40903149-44C19C7F-CA92-4DCA-9427-FCFC7FCBB28FQ42147615-98A02874-11EE-4EEE-B383-D18CF85CE8B3Q43817078-1731A6B4-B6B2-4CC2-A1A7-D04FE677CFFDQ44003038-F4ACD1AC-F101-44F5-9AF3-42AC049061E7Q44227721-819E620E-ADE6-4605-AB62-55369306F589Q46691099-E720C648-0184-42DB-9275-516750BC7B4BQ48534748-0CC1850C-64FD-4B78-AEBB-8FB81E26296BQ50577018-9A38F6DE-728F-4175-A736-BC58E2F1E522Q53474879-48A5AD45-5BBB-4146-BDF6-FDFEB6415683Q55406137-928895B9-316C-42CF-8D53-9E7C87CBA1FEQ56675475-B6E5928A-BB14-4668-81A5-2A0446EFCC7C
P2860
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Severe 5-fluorouracil toxicity ...... mmon pharmacogenetic syndrome.
@en
type
label
Severe 5-fluorouracil toxicity ...... mmon pharmacogenetic syndrome.
@en
prefLabel
Severe 5-fluorouracil toxicity ...... mmon pharmacogenetic syndrome.
@en
P2093
P1433
P1476
Severe 5-fluorouracil toxicity ...... mmon pharmacogenetic syndrome.
@en
P2093
Carpenter JT
P304
P356
10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F
P407
P577
1991-08-01T00:00:00Z